While classic RCC therapies such as VEGF and mTOR targeted therapies are largely ineffective for these tumors, multiple clinical studies suggest that immune checkpoint inhibitors (ICI) may have significant clinical activity in sarcomatoid and rhabdoid RCC5–11. The gene discussed is MTOR; the disease is renal cell carcinoma.